Neuron Guard

Neuron Guard is an Italian medical device company that specializes in targeted temperature management for patients through their innovative technology. The company's flagship product, CB240_Aurora, is a portable hot or cold therapy system designed for selective brain temperature management and is composed of a collar/wrap powered by a smart control unit. Founded in 2013, Neuron Guard has made significant strides in their product development and market expansion. The company has obtained the CE mark as a class II medical device under MDR, allowing it to be sold in 5 countries in Europe. Furthermore, Neuron Guard has also received the ISO Certification 13485, demonstrating their commitment to quality and regulation compliance. With 11 patents and 3 patent pending applications, Neuron Guard has a strong intellectual property portfolio which extends across multiple countries. The company has also conducted a first-in-human pilot trial at the Cambridge University Hospital Neurocritical Care Unit, demonstrating the effectiveness and clinical benefits of CB240_Aurora. This study has been published in Neurocritical Care, showcasing the company's dedication to clinical validation and transparency. Neuron Guard has successfully secured a €550.00K Seed Round investment led by A11 Venture, CDP Venture Capital, Fondo Rilancio Startup in November 2021, highlighting investor confidence in the company's potential. With a focus on biotechnology and healthcare, Neuron Guard is poised for continued growth and impact in the medical device industry.